Study of the Efficacy of Maintenance Therapy by UFT or BCG for Superficial Bladder Cancer Against Recurrence in Urological Oncology Council of Northern Tokyo: EMBARK Study
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 288
- 试验地点
- 1
- 主要终点
- Relapse-free survival rate
研究概览
简要总结
The purpose of this prospective randomized controlled study is to prove the non-inferiority of UFT maintenance therapy to BCG maintenance therapy for preventing recurrences of superficial bladder cancer.
详细描述
Patients who have undergone transurethral resection of a superficial bladder tumor (TUR-Bt) and BCG induction therapy are eligible for enrollment in this study. In principle, BCG induction therapy consists of the successive weekly intravesical administration of 81 mg of BCG-Connaught strain or 80 mg of BCG-Japan strain for 6 weeks after the completion of TUR-Bt.
The patients will be randomly assigned to a BCG maintenance therapy arm or a UFT maintenance therapy arm. The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for BCG maintenance therapy will be the same as that used for BCG induction therapy. Patients in the UFT maintenance therapy arm will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
The primary endpoint of this study is the three-year relapse-free survival rate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Superficial bladder cancer
- •Completion of transurethral resection of bladder tumor (TUR-Bt)
- •Completion of BCG induction therapy after TUR-Bt. In principle, BCG induction therapy consists of the successive weekly intravesical administration of 81 mg of BCG-Connaught strain or 80 mg of BCG-Japan strain for 6 weeks after the completion of TUR-Bt.
- •Age 20 to 80 years
- •ECOG performance status of 0 or 1
- •Bladder capacity ≥ 150 mL
- •Capable of oral UFT administration
- •Expected life prognosis ≥ 3 years
- •Hematopoietic WBC ≥ 3,000/mm^3
- •Neutrophil ≥ 1,500/mm^3
- •Platelet ≥ 100,000/mm^3
- •Hepatic AST and ALT ≤ 2 times upper limit of normal (ULN)
- •Total bilirubin ≤ 1.5 mg/dL
- •Hemoglobin ≤ 9.0 g/dL
- •Creatinine ≤ 1.5 mg/dL
排除标准
- •Bladder cancer located in prostatic part of the urethra
- •Anamnesis of bladder cancer classified as cT2, cT3 or cT4
- •Anamnesis of metastatic bladder cancer
- •Anamnesis of upper urinary tract carcinoma in situ
- •Anamnestic treatment of intravesical BCG administration within previous 6 months
- •Prior anticancer chemotherapy or radiotherapy
- •Severe complication
- •Presence of contraindications for the administration of BCG or UFT
- •Pregnancy, lactation
研究组 & 干预措施
BCG maintenance therapy
干预措施: Bacille Calmette-Guerin (Drug)
UFT maintenance therapy
干预措施: uracil-tegafur (Drug)
结局指标
主要结局
Relapse-free survival rate
时间窗: Three-year
次要结局
未报告次要终点